Aug 28, 2017, 08:00 ET
DUBLIN, Aug. 28, 2017 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that The Allergan Foundation will donate $100,000 to help victims of Hurricane Harvey. The Allergan Foundation donation will be made to the American Red Cross, which has mobilized its resources to respond to the devastation caused by Hurricane Harvey in Texas and across the Gulf Coast region.
"Allergan's 18,000 colleagues extend our thoughts and prayers to the people of Texas and the Gulf Coast who have been affected by the catastrophic winds and rain associated with Hurricane Harvey. We are eager to help and support the work of the American Red Cross in their direct relief efforts," said Brent Saunders, Chairman and CEO of Allergan and Chairman of The Allergan Foundation.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
About The Allergan Foundation
The Allergan Foundation is a U.S.-based, private charitable foundation committed to providing a lasting and positive impact in the communities in which Allergan plc employees live and work.
Established in 1998, The Allergan Foundation focuses its resources primarily on health and human services, selecting initiatives in the areas of ophthalmology, dermatology, neurology, women's health, and a variety of other therapeutic areas that support patient diagnosis and treatment, increase access to health care, and improve quality of life.
In addition, The Allergan Foundation conducts grant making in support of civic and community programs, education and the arts. Since its inception, The Allergan Foundation has distributed over $66 million to a wide variety of philanthropic pursuits – improving lives, elevating communities.
Further extending the scope of philanthropy, in 2011 the Allergan International Foundation was established, supporting a wide range of charitable causes in the UK, Europe, and beyond.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE Allergan plc
Share this article